Product · #11 of 27 · multi-symptom
Amberen Multi-Symptom Menopause Relief
Capsule (2 types: white + orange) from Amberen, made by Alliance Pharmaceuticals. Daily serving: 2 capsules (1 white + 1 orange).
Last updated · Price and ratings checked Nov 19, 2026
In short: Amberen Multi-Symptom Menopause Relief scores 50.9/100 in our ranking (#11 of 27). It costs $0.83 a day at the regular price. Evidence: own trials (n=125, pooled n=227), all manufacturer-linked; best ingredient grade C (Ammonium succinate (Amberen)). No NSF registry listing was confirmed.
Pros
- Widely reviewed: ★ 4.2 from 24,068 Amazon ratings.
- Has its own published product trials (3 in our library); see who funded them below.
- Evidence: own trials (n=125, pooled n=227), all manufacturer-linked.
Cons
- No NSF registry listing confirmed.
- Proprietary blend: some ingredient amounts are not disclosed.
- Legal or regulatory history: see flags below.
Flags
FTC orderFTC noticeWatchdog complaintUndisclosed amounts
Score breakdown
Full label: what's in it
| Ingredient (as labeled) | Per day | Evidence page |
|---|---|---|
| Amberen proprietary compound (Amber-M Complex): ammonium succinate, calcium disuccinate, monosodium L-glutamate, glycine, magnesium disuccinate, zinc difumarate, tocopheryl acetate – totalindividual amounts not disclosed | 400 mg | Ammonium succinate (Amberen) C |
Label from the NIH Dietary Supplement Label Database (2022) and retailer listings; the brand page shows no Supplement Facts text.
Evidence
Our evidence score: 25/40, because: own trials (n=125, pooled n=227), all manufacturer-linked.
Product-level research: All manufacturer-linked; NAMS not recommended. Evidence grade for the branded product: C C.
Ingredient evidence
- Ammonium succinate (Amberen) C (400 mg here)
Amberen's ammonium-succinate blend has been studied for common menopause symptoms* in two placebo-controlled trials and one open-label study, all linked to the manufacturer. The amount of each component is not disclosed. The Menopause Society 2023: Not recommended (Level II) – limited, manufacturer-sponsored.
Studies
Trials of this product
-
Treatment of climacteric symptoms with an ammonium succinate-based dietary supplement: a randomized, double-blind, placebo-controlled trial.
125 Russian women took Amberen or placebo for 3 months. Many symptom scores and anxiety improved more on Amberen. NAMS notes this research was paid for by the manufacturer.
- Who
- 125 women aged 42–60
- Dose
- Amberen (ammonium succinate-based)
- Duration
- 3 months
- Result
- Improvement in 13 of 21 Greene symptoms vs placebo; reduced anxiety; estradiol/leptin changes, weight loss.
- Funding
- Not stated in abstract; manufacturer-sponsored per NAMS 2023. Industry-linked
-
Succinate-Based Dietary Supplement for Menopausal Symptoms: A Pooled Analysis of Two Identical Randomized, Double-Blind, Placebo-Controlled Clinical Trials.
Two identical 90-day Russian trials (227 women) were pooled; Amberen beat placebo on many menopause symptoms. Both trials are manufacturer-linked and have not been repeated independently.
- Who
- 227 women (pooled 2 identical RCTs)
- Dose
- Amberen
- Duration
- 90 days
- Result
- 16 of 21 Greene symptoms improved vs placebo; anxiety down; weight and waist reduced; estradiol rose.
- Funding
- Manufacturer-linked: an author is a paid consultant to Biogix (formerly Lunada Biomedical, Amberen's maker). Industry-linked
-
Clinical Evaluation of Effectiveness and Safety of Combined Use of Dietary Supplements Amberen(®) and Smart B(®) in Women with Climacteric Syndrome in Perimenopause.
106 women took Amberen with a companion product, with no placebo group. Symptoms improved over the study, but without a comparison group this cannot show the product caused the change.
- Who
- 106 perimenopausal women (open-label, no placebo)
- Dose
- Amberen + Smart B
- Duration
- per paper
- Result
- Greene, anxiety, depression and well-being scores improved from baseline.
- Funding
- Not stated in abstract (product study). Funding not stated
Studies on its ingredients (1)
-
Multivessel Spontaneous Coronary Artery Dissection: Amberen as a Possible Risk Factor.
A single case report described a rare heart-artery tear in a woman taking Amberen. One case cannot prove cause, but it is worth knowing.
- Who
- 1 case
- Dose
- Amberen
- Duration
- n/a
- Result
- Case of multivessel spontaneous coronary artery dissection possibly linked to Amberen.
- Funding
- Case report. Independent / academic
The Menopause Society's 2023 statement is in the study library.
Price
| Regular one-time price | $24.97 (60 units, 30 days at label dose) |
|---|---|
| Cost per day | $0.83 |
| Subscription | Amazon S&S up to 30% off |
| Price notes | amberen.com no longer sells direct (no price, links to retailers). Price = Amazon B00KFA94FC (sold by Alliance Pharma) $24.97; 60-day $44.99. |
| In stock when checked | Yes |
| Checked | Nov 19, 2026 |
Ratings
Amazon: ★ 4.2 from 24,068 ratings on Amazon (checked Nov 19, 2026)
Star ratings reflect buyer satisfaction, not clinical effect.
Certifications and claims
Verified in a public registry
- No registry listing found.
Claims made by the brand
- “clinically proven (own 90-day placebo-controlled study)” Brand claim
- “free from drugs, hormones, soy, gluten, caffeine” Brand claim
Registry check: NSF/ANSI 173 ('Amberen','Alliance'): not found
Who's behind it
| Brand | Amberen |
|---|---|
| Owner / company | Alliance Pharmaceuticals Ltd (UK; US entity Alliance Pharma Inc). Originally Lunada Biomedical. |
| Founders | Not stated on the pages we read. |
| Where it's made | not stated. |
| Medical advisors named | None named on the pages we read. |
| Source | amberen.com · alliancepharmaceuticals.com |
Flags & safety
Legal, regulatory and quality flags
- FTC v. Lunada Biomedical (2015–2016): stipulated order bars unsubstantiated weight-loss and menopause-relief claims; $40M judgment suspended on $250k payment. ftc.gov
- TINA.org complaint to FTC/FDA (Oct 2024) alleging Amberen marketing violates the 2016 order; FTC Notice of Penalty Offenses sent to Alliance (Apr 2023). truthinadvertising.org
- Proprietary blend: individual succinate amounts not disclosed.
Ingredient safety notes
- Ammonium succinate (Amberen): One case report of spontaneous coronary artery dissection (causality unproven). Trials reported estradiol increase.
Sources
Talk to a clinician first
The Menopause Society's 2023 nonhormone position statement does not recommend any dietary supplement or herbal remedy for hot flashes, because the research is limited or mixed. Hormone therapy is an option for many women, and the statement lists non-hormonal options with evidence behind them: CBT, clinical hypnosis, SSRIs/SNRIs, gabapentin, fezolinetant (Level I), oxybutynin (I–II), weight loss, stellate ganglion block (II–III).
If hot flashes, night sweats, sleep or mood are affecting your life, talk to a clinician first. If you still want to try a supplement, the rankings below show what is actually in each one, what the research found, and who is behind it. Sources: position statement (PDF) · PubMed.
*These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. Solynes does not sell supplements; descriptions summarize published research and are not medical advice.